Autopsy report · NCT01103583

Hydroxyurea in Primary Progressive Multiple Sclerosis

“No efficacy (interim.analysis)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months before it started.
• 33 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

S. Andrea Hospital

Sponsor type

University, hospital or other

Conditions

Multiple Sclerosis

Interventions

Hydroxyurea; placebo

Participants

33

Sites

2

Countries

Italy

Trials that died the same way

• A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
  “Lack of efficacy determined at interim analysis” (87% match in meaning)
• A Pilot Study of Candesartan as a Treatment for Cocaine Dependence
  “Results of interim efficacy analysis showed results were not promising.” (83% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (81% match in meaning)
• LBH589 in Refractory Myelodysplastic Syndromes (MDS)
  “Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.” (77% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.